A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Phase 1/2 Completed 24 enrolled Bristol-Myers Squibb

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-791325 in subjects with chronic hepatitis C infection

Timeline

Start: 2008-05
Primary completion: 2009-06
Completion: 2009-06

Publications

Sims KD, Lemm J, Eley T, Liu M, Berglind A, Sherman D, Lawitz E, Vutikullird AB, Tebas P, Gao M, Pasquinelli C, Grasela DM. Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection. Antimicrob Agents Chemother. 2014 Jun;58(6):3496-503. doi: 10.1128/AAC.02579-13. Epub 2014 Apr 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Beclabuvir	Small molecule	100 mg	Oral
Subject	Beclabuvir	Small molecule	300 mg	Oral
Subject	Beclabuvir	Small molecule	600 mg	Oral
Subject	Beclabuvir	Small molecule	900 mg	Oral

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Summary

Timeline

Publications

Drugs

Indications